According to reports from CNBC TV18, Sun Pharma Advanced Research Company reported a consolidated net loss of ₹20.78 crore for the quarter ended June 2026, representing a significant improvement from the net loss of ₹51.87 crore recorded in the corresponding quarter of the previous financial year. The company demonstrated substantial operational recovery during the quarter, with the EBITDA loss narrowing to ₹27 crore compared to ₹48.2 crore in the same quarter last year. As per the latest financial results, the standalone net loss was ₹2,098 lakhs for Q1FY27, narrowing from ₹5,203 lakhs in Q1FY26, though this represents a 6% year-on-year increase in absolute terms. The revenue for Q1 FY27 was ₹3,992 lakhs with a net loss of ₹2,098 lakhs, reflecting normalization after a one-time PRV sale in Q4 FY26. The basic and diluted EPS for Q1 FY27 was ₹(0.65) standalone and ₹(0.64) consolidated.
As reported by CNBC TV18, the company's sales surged to ₹40 crore in Q1 FY27, compared to ₹9.6 crore in the same quarter of the previous financial year, representing a dramatic multi-fold increase in revenue. According to the latest results, total revenue from operations stood at ₹3,992 lakhs in Q1FY27, up significantly from ₹964 lakhs in Q1FY26, primarily due to the recognition of ₹2,921 lakhs in revenue relating to non-refundable consideration following the mutual termination of a licensing agreement with CMS Bridging DMCC. This substantial revenue growth indicates strong business momentum and market expansion during the quarter, marking a significant improvement in the company's top-line performance.
According to the financial data reported by CNBC TV18, the company's operating profit margin (OPM) stood at -85.17% in the June 2026 quarter, compared to -540.25% in the corresponding quarter of the previous year. The PBDT (Profit Before Depreciation and Tax) was ₹-18.47 crore, while PBT (Profit Before Tax) was ₹-20.67 crore for the quarter ended June 2026. As per the latest results, total expenses increased to ₹8,456 lakhs from ₹7,069 lakhs in the previous year, with employee benefits expense rising to ₹2,416 lakhs from ₹2,768 lakhs, while clinical trial and product development expenses increased to ₹1,326 lakhs from ₹554 lakhs. The EBITDA loss narrowing to ₹27 crore from ₹48.2 crore year-on-year demonstrates improved operational efficiency despite remaining in the red at both net profit and operating levels.
Post earnings announcement, shares of Sun Pharma Advanced Research Company were trading at ₹209.11 on the NSE as of 2:27 pm, down ₹4.10, or 1.92%, according to CNBC TV18. The market reaction reflects investor assessment of the company's improved financial performance despite remaining in losses. The 60% reduction in net loss from ₹51.87 crore to ₹20.78 crore indicates effective cost management and operational efficiency improvements during the quarter. Additionally, the company noted that during the quarter ended March 31, 2026, it recognized income of ₹184,002 lakhs regarding a Priority Review Voucher (PRV) granted by the USFDA for Sezaby®, which was sold on April 30, 2026, for USD 195 million. On May 19, 2026, the company allotted 3,85,10,000 warrants to Shanghvi Finance Private Limited at an issue price of ₹155.80 each, raising capital to support future operations. The company is currently prioritizing oncology and immunology assets while pursuing cash catalysts and clinical milestones.
